This trial evaluated quality of life (QoL) using the EORTC QLQ-C30 and the EORTC QLQ-MY20 instruments in 90 patients with relapsed/refractory multiple myeloma during induction and maintenance therapy with eight cycles of ixazomib-thalidomide-dexamethasone, followed by 12 months of ixazomib maintenance therapy. When patient's baseline QoL was compared with data of the general population, a significant impairment in health-related QoL, physical, role, and social functioning and several other dimensions, as well as more pain and fatigue, was noted. Induction therapy resulted in significant improvement of pain and worsening of neuropathy, with no significant variation of other parameters. During maintenance treatment, scores for most dimensions including health-related QoL, physical functioning and pain, improved, while for neuropathy no improvement was observed. Time to deterioration (≥10 score points) of health-related QoL, physical functioning, pain, and neuropathy was distinctly shorter than time to progression. Health-related QoL and physical functioning at baseline correlated with overall survival.

CCRC Cancer Clinical Research Consulting Düsseldorf Germany

Department of Hematology University of Leipzig Leipzig Germany

Department of Internal Medicine 1 Ordensklinikum Linz Barmherzige Schwestern Linz Austria

Department of Internal Medicine 3 Kepler Universitaetsklinikum GmbH Med Campus 3 Linz Austria

Department of Internal Medicine 3 with Haematology Medical Oncology Hemostaseology Infectiology and Rheumatology Oncologic Center Paracelsus Medical University Salzburg Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials Cancer Cluster Salzburg Austria

Department of Internal Medicine 5 Hematology and Oncology Medical University Innsbruck Innsbruck Austria

Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic

Department of Medicine 1 Center for Oncology and Hematology Wilhelminen Hospital Vienna Austria

Department of Medicine 1 Hematology with Stem Cell Transplantation Hemostaseology and Medical Oncology Ordensklinikum Linz Elisabethinen Linz Austria

Department of Oncology Hematology and Gastroenterology Academic Teaching Hospital Feldkirch Feldkirch Austria

Division of Hematology and Medical Oncology Department of Internal Medicine 2 Wuerzburg University Medical Center Wuerzburg Germany

Fakultní Nemocnice Ostrava Ostrava Czech Republic

Medical Department Division of Psychosomatic Medicine Charité Universitätsmedizin Berlin Germany

Oncotyrol Center for Personalized Cancer Medicine Innsbruck Austria

University Medical Center of Hamburg Eppendorf Hamburg Germany

Wilhelminen Cancer Research Institute Department of Medicine 1 Center for Oncology and Hematology Wilhelminen Hospital Vienna Austria

Citace poskytuje Crossref.org

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life